L. Ranganath

Attenuated GLP-1 secretion in obesity: cause or consequence?

L. Ranganath, J Beety, LM Morgan et al. · Gut · 1996 · 386 citations · Full text

Life Sciences, Endocrinology, Physiology +15

Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study

Michael Mannstadt, B.L. Clarke, Tamara Vokes et al. · The Lancet Diabetes & Endocrinology · 2013 · 303 citations

Medicine, Biochemistry, Endocrinology +9

Receptors and effects of gut hormones in three osteoblastic cell lines

Elda Pacheco‐Pantoja, L. Ranganath, James A. Gallagher et al. · BMC Physiology · 2011 · 167 citations · Full text

Medicine, Cell Biology, Endocrinology +17

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment

L. Ranganath, Anna M. Milan, Andrew T. Hughes et al. · Annals of the Rheumatic Diseases · 2014 · 157 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial

L. Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux et al. · The Lancet Diabetes & Endocrinology · 2020 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3